trending Market Intelligence /marketintelligence/en/news-insights/trending/llhflb68-edtjzhph_vlbw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Valeant to refinance existing credit agreement, raise new debt

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Valeant to refinance existing credit agreement, raise new debt

Valeant Pharmaceuticals International Inc. said it was refinancing some of its existing debt.

The company plans to borrow $3.82 billion in new term B loans that replace its current credit agreements.

The Canadian drugmaker said the new credit agreement will modify the covenants, lower the interest rates and add its unit Valeant Pharmaceuticals International as a co-borrower.

The company's unit may also issue $750 million of secured debt securities and $750 million of unsecured debt securities.

Valeant, which is renaming itself as Bausch Health Companies Inc., said the new loan will also be used to redeem certain senior notes.

The senior notes to be redeemed include the 5.375% senior notes due 2020, 6.375% senior notes due 2020, 6.75% senior notes due 2021 and 7.25% senior notes due 2022.